{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-096035","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.118265+00:00","generated_at":"2026-05-31T06:39:05.808275+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Praxis Precision Medicines announces positive topline results from EMBOLD study of relutrigine in SCN2A/SCN8A DEE","bullets":["Placebo-adjusted reduction of 46% in countable motor seizures for relutrigine-treated patients.","5 of 16 randomized patients achieved 28-day seizure-free status on relutrigine vs. none on placebo.","Relutrigine was generally safe and well tolerated; no patients discontinued due to adverse events.","Eight patients completed ≥1 OLE period with median motor seizure reduction of 75%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-096035","json":"https://secwatch.observer/filing/0001104659-24-096035.json","markdown":"https://secwatch.observer/filing/0001104659-24-096035.md","text":"https://secwatch.observer/filing/0001104659-24-096035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000110465924096035/0001104659-24-096035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000110465924096035/tm2423220d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:39:05.808275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}